Cost of illness for COVID-19 patients at Dr. Loekmono Hadi Regional Hospital, Kudus Regency
Keywords:
Cost of illness, COVID-19, RSUD dr. Loekmono Hadi KudusAbstract
This research aims to determine the total difference in the patient's real cost of this research's purpose is to find out the total difference in the real cost of the COVID-19 hospital patient which is viewed by age factors, degree of COVID-19 severity, comorbide and type of therapy with Keputusan Menteri Kesehatan claims. The study was a pharmakoeconomic analysis based on the hospital's perspective on direct medical costs, retrospective method of data fetching through patient medical records during October 2020 October 2021. The variables in this study are composed of free variables of age, comorbide, lengthy treatment and type, as variables depending on the cost of the patient's rill. The method of analysis t test for the 2 different groups the rate of 95%. The study showed that the total cost of Covid-19 disease was the October 2020–Oktober 2021 period of 3,749,452,350 is the result of the exact sum of 360 samples of the COVID-19 patients. COVID-19 patient's real cost of rill indicates significant differences in age, comorbide, degree of severity, lengthy treatment and therapy of long treatment in the form of p <.05 shows a correlation of age cost, comorbide, degree of severity, and treatment.
Downloads
References
Acosta, E. P., Jester, P., Gal, P., Wimmer, J., Wade, J., Whitley, R. J., & Kimberlin, D. W. (2010). Oseltamivir dosing for influenza infection in premature neonates. Journal of Infectious Diseases, 202(4), 563–566. https://doi.org/10.1086/654930 DOI: https://doi.org/10.1086/654930
Andayani, T. M. (2013). Farmakologi Prinsip Dan Metodelogi.
B Wibowo. (2014). “INA CBG’s Membuat Biaya Kesehatan Lebih Efektif”,. Info BPJS Kesehatan, VIII.
Bartsch, S. M., Ferguson, M. C., McKinnell, J. A., O’shea, K. J., Wedlock, P. T., Siegmund, S. S., & Lee, B. Y. (2020). The potential health care costs and resource use associated with COVID-19 in the United States. Health Affairs,39(6), 927–935. https://doi.org/10.1377/hlthaff.2020.00426 DOI: https://doi.org/10.1377/hlthaff.2020.00426
Bootman, J.L., Towsend, R.., dan McGhan, W. (2005). Principles of pharmacoeconomics, 3 rd. ed. Harvey Whitney Books Company, USA. Byford, S. (2000). Economic Note: Cost of illness studies. Bmj, 320(7245), 335– 1335. https://doi.org/10.1136/bmj.320.7245.1335 DOI: https://doi.org/10.1136/bmj.320.7245.1335
C sie maszko. (2020). Corona virus out breaks labeled pandemi WHO. https://www.nbcnews.com/health-news/coronavirus-outbreak-labeledpandemi-world-health-organization-n1155741
Chandwani, A., & Shuter, J. (2008). Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. In Therapeutics and Clinical Risk Management (Vol. 4, Issue 5). DOI: https://doi.org/10.2147/TCRM.S3285
Clabaugh, G., & Ward, M. M. (2008). Cost-of-illness studies in the United States: A systematic review of methodologies used for direct cost. Value in Health, 11(1), 13–21. https://doi.org/10.1111/j.1524- 4733.2007.00210.x DOI: https://doi.org/10.1111/j.1524-4733.2007.00210.x
Depkes, R. (2014). Peraturan Menteri Kesehatan Republik Indonesia Nomor 27 Tahun 2014 tentang Petunjuk Teknis Sistem Indonesian Case Base Groups (INA-CBGs). Kementerian Kesehatan RI, 50.
Du, Z., Zhu, F., Guo, F., Yang, B., & Wang, T. (2020). Detection of antibodies against SARS-CoV-2 in patients with COVID-19. Journalof Medical Virology,92(10), 1735–1738. https://doi.org/10.1002/jmv.25820 DOI: https://doi.org/10.1002/jmv.25820
Gottlieb, R. L., Vaca, C. E., Paredes, R., Mera, J., Webb, B. J., Perez, G., Oguchi, G., Ryan, P., Nielsen, B. U., Brown, M., Hidalgo, A., Sachdeva, Y., Mittal, S., Osiyemi, O., Skarbinski, J., Juneja, K., Hyland, R. H., Osinusi, A., Chen, S., … Hill, J. A. (2022). Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. New England Journal of Medicine, 386(4), 305–315. https://doi.org/10.1056/nejmoa2116846 DOI: https://doi.org/10.1056/NEJMoa2116846
Hasbullah, P. (2020). Rata-rata Biaya Perawatan Covid-19 per orang Rp.184 juta.
Haq, A. D., Nugraha, A. P., Wibisana, I. K. G. A., Anggy, F., Damayanti, F., Syifa, R. R. D. M., Widhiani, N. P. V., & Warnaini, C. (2021). Faktor – Faktor Terkait Tingkat Keparahan Infeksi Coronavirus Disease 2019 (COVID-19): Sebuah Kajian Literatur. JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia, 9(1), 48–55. https://doi.org/10.53366/jimki.v9i1.338 DOI: https://doi.org/10.53366/jimki.v9i1.338
Hong Liu, Shiyan Chen, and H. L., & Disclaimer. (2020). Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis. DOI: https://doi.org/10.14336/AD.2020.0502
Ismaila, H., Asamani, J. A., Lokossou, V. K., Oduro-Mensah, E., Nabyonga- Orem, J., & Akoriyea, S. K. (2021). The cost of clinical management of SARS- COV-2 (COVID-19) infection by level of disease severity in Ghana: a protocol-based cost of illness analysis. BMC Health Services Research, 21(1), 1–10. https://doi.org/10.1186/s12913-021-0710-z DOI: https://doi.org/10.1186/s12913-021-07101-z
Istiqomah, A. N. (2016). Analisis Burden of Disease Akibat Hipertensi Pada Masyarakat Dengan Status PBI JKN Di Kabupaten Pamekasan. Skripsi. Program Sarjana Program Studi Kesehatan Masyarakat Universitas Airlangga. Surabaya. Analisis Burden of Disease Akibat Hipertensi Pada Masyarakat Dengan Status PBI JKN Di Kabupaten Pamekasan. Skripsi. Program Sarjana Program Studi Kesehatan Masyarakat Universitas Airlangga. Surabaya. DOI: https://doi.org/10.29241/jmk.v2i2.58
Jo, C. (2014). Studi biaya penyakit: konsep, ruang lingkup, dan metode. November, 327–337.
Jovic, T. H., Ali, S. R., Ibrahim, N., Jessop, Z. M., Tarassoli, S. P., Dobbs, T. D., Holford, P., Thornton, C. A., & Whitaker, I. S. (2020). Could vitamins help in the fight against covid-19? In Nutrients (Vol. 12, Issue 9, pp. 1–30). MDPI AG. https://doi.org/10.3390/nu12092550 DOI: https://doi.org/10.3390/nu12092550
Kemenkes. (2013). Kategori Umur Menurut WHO.
Kemenkes RI. (2020). Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/446/2020 Tentang Petunjuk Teknis Klaim Penggantian Biaya Pelayanan Pasien Penyakit Infeksi Emerging Tertentu Bagi Rumah Sakit Yang Menyelenggarakan Pelayanan Corona Virus Disease 2019 (C. Keputusan Menteri Kesehatan Republik Indonesia, 1(1),4–23. Https://wellness.journalpress.id/wellness/article/view/21026
Keputusan Menteri Kesehatan Republik Indonesia. (2021). Keputusan Menteri Kesehatan republik indonesia nomor Hk.01.07/menkes/5671/2021 tentang manajemen klinis tata laksana. 3, 1–106.
Larg, A., & Moss, J. R. (2011). Cost-of-illness studies: A guide to critical evaluation.PharmacoEconomics,29(8),653–671. https://doi.org/10.2165/11588380-000000000-00000 DOI: https://doi.org/10.2165/11588380-000000000-00000
Liza, A. Y., Laksmitawati, D. R., Sarnianto, P., & Anggeraini, S. D. (2022). Analisis Klaim Pembiayaan KEMENKES dan Biaya riil pada covid-19 di RSUD Cempaka Putih Jakarta. Jurnal Kesehatan, 13(2), 172–186. https://doi.org/10.38165/jk.v13i2.323 DOI: https://doi.org/10.38165/jk.v13i2.323
Malekzadeh, H., Golpayegani, M., Ghodsi, Z., Sadeghi-Naini, M., Asgardoon, M., Baigi, V., Vaccaro, A. R., & Rahimi-Movaghar, V. (2021). Direct Cost of Illness for Spinal Cord Injury: A Systematic Review. Global Spine Journal. https://doi.org/10.1177/21925682211031190 DOI: https://doi.org/10.1177/21925682211031190
Maltezou, H. C., Giannouchos, T. V., Pavli, A., Tsonou, P., Dedoukou, X., Tseroni, M., Papadima, K., Hatzigeorgiou, D., Sipsas, N. V., & Souliotis, K. (2021). Costs associated with COVID-19 in healthcare personnel in Greece: a cost-of-illness analysis. Journal of Hospital Infection, 114, 126–133. https://doi.org/10.1016/j.jhin.2021.04.018 DOI: https://doi.org/10.1016/j.jhin.2021.04.018
Medina, M. A. P. (2020). Age as a Risk Factor of COVID-19 Mortality in the Philippines. DOI: https://doi.org/10.2139/ssrn.3579145
Nurhayatun1, S., Fitriyanti2, N., Sonia3, D., Medis, R., Kesehatan, I., Piksi, P., & Bandung, G. (2021). Analisis Average Length of Stay (AVLOS) kasus Covid-19 diRumah Sakit X Bandung (Vol. 4, Issue 3). http://jurnal.umpar.ac.id/index.php/makes DOI: https://doi.org/10.31850/makes.v4i3.988
Patria Jati, S., Budiyono, Tiyas Budiyanti, R., Suhartono, Ginandjar, P., Sriatmi, A., & Nandini, N. (2020). Cost Estimates Related to COVID- 19 Treatment in Indonesia: What Should be Concerned? E3S Web of Conferences, 202. https://doi.org/10.1051/e3sconf/202020212012 DOI: https://doi.org/10.1051/e3sconf/202020212012
Purbaningsih, S. (2020). Cost of Illness. Pharmacoeconomics, 51–60. https://doi.org/10.1201/9781420084405-8 DOI: https://doi.org/10.1201/9781420084405-8
Pusat, U., & Kandou, P. R. D. (2019). 26532-54345-1-Sm (1). 2(2), 86–93. DOI: https://doi.org/10.35799/pmj.2.2.2019.26532
Rascati, K. L. (2014). Essentials of Pharmacoeconomics. Philadelphia: Lippincott Williams & Wilkins Wolther Klower Business. 12–13, 21.
Rahmawati, C., Nurbaety, B., Qiyaam, N., Dini, S., & Maftuhah, L. (2022). Cost of illness for COVID-19 in patients in West Nusa Tenggara, Indonesia. Pharmacy Education, 22(2), 66–69. akses pada 27 Agustus 2022 pukul 22.00 WIB https://doi.org/10.46542/pe.2022.222.6669 DOI: https://doi.org/10.46542/pe.2022.222.6669
Rees, E. M., Nightingale, E. S., Jafari, Y., Waterlow, N. R., Clifford, S., Carl, C. A., Group, C. W., Jombart, T., Procter, S. R., & Knight, G. M. (2020). COVID-19 length of hospital stay: A systematic review and data synthesis. BMC Medicine, 18(1). https://doi.org/10.1186/s12916-020-01726-3 DOI: https://doi.org/10.1186/s12916-020-01726-3
Rezkita, B. E., Irving, S., Pribadi, R. R., & Simadibrata, M. (2022). Efektivitas Efikasi Pemberian Antivirus Favipiravir pada Pasien Covid-19: Evidence Based Case Report. KELUWIH: Jurnal Kesehatan Dan Kedokteran, 3(2). https://doi.org/10.24123/kesdok.v3i2.4786 DOI: https://doi.org/10.24123/kesdok.V3i2.4786
Rice, D. P. 2000. C. (2000). No Title. Cost of Illness Studies: What Is Good about Them ?. Journal of Injury Prevention, 6, 177–179. DOI: https://doi.org/10.1136/ip.6.3.177
Rochmah, T. N. (2014). Perhitungan Burden of Disease (Beban Ekonomi atas Episode Sakit Kasus Stroke dan Jantung. Lecture Handout. Universitas Airlangga. Surabaya. Perhitungan Burden of Disease (Beban Ekonomi Atas Episode Sakit Kasus Stroke Dan Jantung. Lecture Handout. Universitas.
Sam, K. G., Kuriachan, M., &Philip, S. (2009). Pharmaco economics : Cost of Illness Studies. Hygeia, 1(1),46–49.
Samad, N., Sodunke, T. E., Abubakar, A. R., Jahan, I., Sharma, P., Islam, S., Dutta, S., & Haque, M. (2021). The implications of zinc therapy in combating the covid-19 global pandemic. In Journal of Inflammation Research (Vol. 14, pp. 527–550). Dove Medical Press Ltd. https://doi.org/10.2147/JIR.S295377 DOI: https://doi.org/10.2147/JIR.S295377
Sanchez, L. (2005). Pharmacoeconomics: Principles, Methods, and Applications, dalam: Pharmacotherapy A Pathophysiologic Approach. McGraw-Hill, United States of America.
Sanyaolu, A., Okorie, C., Marinkovic, A., Patidar, R., Younis, K., Desai, P., Hosein, Z., Padda, I., Mangat, J., & Altaf, M. (n.d.). Comorbidity and its Impact on Patients with COVID-19. https://doi.org/10.1007/s42399-020-00363-4/Published
Segel, J. E. (2006). Cost-of-Illness Studies - A Primer. Chapel Hill: RTI- UNC Center of Excellence in Health Promotion Economics. Cost-of- Illness Studies- A Primer. Chapel Hill: RTI-UNC Center of Excellence in Health Promotion Economics.
Setyarini, Y., Suryawati, C., Pawelas Arso, S., Kariadi Semarang, R., & Kesehatan Masyarakat, F. (n.d.-a). Analisis Pembiayaan COVID-19 di RSUP dr. Kariadi Semarang.
Sugiyono. (2016). Metode Penelitian Kuantitatif, Kualitatif dan R&D. Bandung: PT Alfabet.
Tarricone, R. (2006). Cost-of-illness analysis. What room in health economics? Health policy (Amsterdam, Netherlands), 77: 51–63. DOI: https://doi.org/10.1016/j.healthpol.2005.07.016
Taylor, D. H. dan F. A. S. (2000). How Much Do Persons with Alzheimer’s Disease Cost Medicare? Journal of The American Getriatrics Society. 639– 646. DOI: https://doi.org/10.1111/j.1532-5415.2000.tb04721.x
Trask, L. S. (2011). Trask, L. S., 2011, Chapter 1. Pharmacoeconomics: Principles, Methods, and Applications. In J. T. DiPiro, R. L. Talbert, G. C. Yee, G. R. Matzke, B. G. Wells, & L. M. Posey (Eds.), Pharmacotherapy: A Pathophysiologic Approach, 8e. New York, NY: The McGraw. veryti. (n.d.).
Wibowo, B. (2013). Tarif INA-CBGs Untuk Jaminan Kesehatan Nasional 2014.
Zhou, E. W. (2020). 101 Tips Berbasis Sains. Buku Panduan Pencegahan Coronavirus 101 Tips Berbasis Sains Yang Dapat Menyelamatkan Hidup Anda, 120. https://fin.co.id/wp- content/uploads/2020/03/Buku-Panduan-Pencegahan-oronavirus- 101-Tips-Berbasis-Sains.pdf
Published
How to Cite
Issue
Section
Copyright (c) 2025 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
